Germany-based Medigene’s (FSE: MDG) shares were down 3.7% at 1.04 euros in late afternoon trading, after it revealed a collaboration with China’s WuXi Biologics (HK: 2269).
The companies have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors.
They explained that the collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics’ unique anti-CD3 monoclonal antibody (MAb), its industry-leading TCE platform and proprietary bispecific antibody platform WuXiBody.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze